Neurodegeneration in diabetes mellitus

Advances in Experimental Medicine and Biology

Volumn 724, Issue , 2012, Pages 258-265

  Umegaki, Hiroyuki ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; INSULIN; INSULINASE; TAU PROTEIN;

ALZHEIMER DISEASE; ARTICLE; BLOOD GLUCOSE MONITORING; COGNITIVE DEFECT; DISEASE ASSOCIATION; DISEASE COURSE; HUMAN; HYPERTENSION; MULTIINFARCT DEMENTIA; NERVE DEGENERATION; NEUROIMAGING; NEUROPATHOLOGY; NON INSULIN DEPENDENT DIABETES MELLITUS; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN METABOLISM; PROTEIN PHOSPHORYLATION; RISK FACTOR; VASCULAR DISEASE; BRAIN; DEGENERATIVE DISEASE; GLUCOSE BLOOD LEVEL; PATHOLOGY; REVIEW;

BLOOD GLUCOSE; BRAIN; COGNITION DISORDERS; DIABETES MELLITUS, TYPE 2; HUMANS; NEURODEGENERATIVE DISEASES;

EID: 84859498019     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4614-0653-2_19     Document Type: Article

References (51)

1. Stewart R, Liolitsa D. Type 2 diabetes mellitus, cognitive impairment and dementia. Diabetic Medicine 1999; 16:93-112.
2. Li L, Holscher C. Common pathological processes in Alzheimer disease and type 2 diabetes: a review. Brain Res Rev 2007; 56:384-402.
3. Ott A, Stolk RP, van Harskamp F et al. Diabetes mellitus and the risk of dementia: The Rotterdam Study.Neurology 1999; 58:1937-1941.
4. Arvanitakis Z, Wilson RS, Bienias JL et al. Diabetes mellitus and risk of Alzheimer's disease and decline in cognitive function. Arch Neurol 2004; 61:661-666.
5. Peila R, Rodriguez BL, Launer LJ. Honolulu-Asia Aging Study. Type 2 diabetes, APOE gene and the risk fordementiaandrelatedpathologies. Diabetes 2002; 51:1256-1262.
6. Peila R, Rodriguez BL, White LR et al. Fasting insulin and incident dementia in an elderly population of Japanese-American men. Neurology 2004; 63:228-233.
7. Vermeer SE, Koudstaal PJ, Oudkerk M et al. Prevalence and risk factors of silent brain infarcts in the population-based Rotterdam Scan Study. Stroke 2002; 33:21-25.
8. de Leeuw FE, de Groot JC, Achten E et al. Prevalence of cerebral white matter lesions in elderly people: a population based magnetic resonance imaging study. The Rotterdam Scan Study. J Neurol Neurosurg Psychiatry 2001; 70:9-14.
9. den Heijer T, Vermeer SE, van Dijk EJ et al. Type 2 diabetes and atrophy of medial temporal lobe structures on brain MRI. Diabetologia 2003; 46:1604-1610.
10. Korf ES, White LR, Scheltens P et al. Brain aging in very old men with type 2 diabetes: the Honolulu-Asia Aging Study. Diabetes Care 2006; 29:2268-2274.
11. Korf ES, van Straaten EC, de Leeuw FE et al. LADIS Study Group. Diabetes mellitus, hypertension and medial temporal lobe atrophy: the LADIS study. Diabet Med 2007; 24:166-171.
12. Yamagishi S, UedaS, OkudaS. Food-derived advanced glycation end products (AGEs): a novel therapeutic target for various disorders. Curr Pharm Des 2007; 13:2832-2836.
13. Valente T, Gella A, Fernandez-Busquets X et al. Immunohistochemical analysis of human brain suggests pathological synergism of Alzheimer's disease and diabetes mellitus. Neurobiol Dis 2010; 37:67-76.
14. Block ML, Zecca L, Hong JS. Microglia-mediated neurotoxicity: uncovering the molecular mechanisms. Nat Rev Neurosci 2007; 8:57-69.
15. Evans JL, Goldfrne ID, Maddux BA et al. Oxidative stress and stress-activated signaling pathways: a unifying hypothesis of type 2 diabetes. Endocr Rev 2002; 23:599-622.
16. Moreira PI, Santos MS, Seica R et al. Brain mitochondrial dysfunction as a link between Alzheimer's disease and diabetes. J Neurol Sci 2007; 257:206-214.
17. Watson GS, Craft S. The role of insulin resistance in the pathogenesis of Alzheimer's disease: implications fortreatment. CNS Drugs 2003; 17:27-45.
18. Davis SN, Granner DK. Insulin, oral hypoglycemic agents and the pharmacology of the endocrine pancreas. In: Hardman JG, Gilman AG, Limbird LE, eds. Gilman and Goodman's the Pharmacological Basis of Ttherapeutics, 9th. New York: McGraw-Hill, 1996:1487-1517.
19. Woods SC, Seeley RJ, Baskin DG et al. Insulin and the blood-brain barrier (BBB). Curr Pharm Des 2003; 9:795-800.
20. Havrankova J, Roth J, Brownstein M. Insulin receptors are widely distributed in the central nervous system oftherat. Nature 1978; 272:827-829.
21. Freychet P. Insulin receptors and insulin action in the nervous system. Diab Metab Res Rev 2000; 16:390-392.
22. Rivera EJ, Goldin A, Fulmer N et al. Insulin and insulin-like growth factor expression and function deteriorate with progression of Alzheimer's disease: link to brain reductions in acetylcholine. J Alzheimers Dis 2005; 8:247-268.
23. Lacor PN, Buniel MC,Chang L et al. Synaptic targeting by Alzheimer's-related amyloid beta oligomers. J Neurosci 2004; 24:10191-10200.
24. Walsh DM, Klyubin I, Fadeeva JV et al. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 2002; 416:535-539.
25. Sato T, Hanyu H, Hirao K et al. Efficacy of PPAR-gamma agonist pioglitazone in mild Alzheimer disease. Neurobiol Aging 2009. [Epub ahead of print]
26. Zhao WQ, Townsend M. Insulin resistance and amyloidogenesis as common molecular foundation for type 2 diabetes and Alzheimer's disease. Biochim Biophys Acta 2009; 1792:482-496.
27. Craft S, Peskind E, Schwartz MW et al. Cerebrospinal fluid and plasma insulin levels in Alzheimer's disease: relationship to severity of dementia and apolipoprotein E genotype. Neurology 1998;50:164-168.
28. Reger MA, Watson GS, Green PS et al. Intranasal insulin improves cognition and modulates beta-amyloid in early AD. Neurology 2008; 70:440-448.
29. Thorne RG, Pronk GJ, Padmanabhan V et al. Delivery of insulin-like growth factor-I to the rat brain and spinal cord along olfactory and trigeminal pathways following intranasal administration. Neuroscience 2004; 127:481-496.
30. Benedict C, Hallschmid M, Hatke A et al. Intranasal insulin reportedly improves memory and attention in humans. Psychoneuroendocrinology 2004; 29:1326-1334.
31. Beeri MS, Silverman JM, Davis KL et al. Type 2 diabetes is negatively associated with Alzheimer's disease neuropathology. J Gerontol A Biol Sci Med Sci 2005; 60:471-475.
32. Arvanitakis Z, Schneider JA, Wilson RS et al. Diabetes is related to cerebral infarction but not to AD pathology in older persons. Neurology 2006; 7:960-1965.
33. de la Torre JC. Is Alzheimer's disease a neurodegenerative or a vascular disorder? Data, dogma and dialectics. Lancet Neurol 2004; 3:184-190.
34. Riekse RG, Leverenz JB, McCormick W et al. Effect of vascular lesions on cognition in Alzheimer's disease: a community-based study. J Am Geriatr Soc 2004; 52:1442-1448.
35. Akisaki T, Sakurai T, Takata T et al. Cognitive dysfunction associates with white matter hyperintensities and subcortical atrophy on magnetic resonance imaging of the elderly diabetes mellitus. Japanese elderly diabetes intervention trial (J-EDIT). Diabetes Metab Res Rev 2006; 22:376-384.
36. Umegaki H, Kawamura T, Mogi N et al. Glucose control levels, ischaemic brain lesions and hyperinsulinaemia were associated with cognitive dysfunction in diabetic elderly. Age Ageing 2008; 37:458-461.
37. Suzuki M, Umegaki H, Ieda S et al. Factors associated with cognitive impairment in elderly patients with diabetes mellitus. J Am Geriatr Soc 2006; 54:558-559.
38. Sonnen JA, Larson EB, Brickell K et al. Different patterns of cerebral injury in dementia with or without diabetes. Arch Neurol 2009; 66:315-322.
39. Arvanitakis Z, Wilson RS, Bienias JL et al. Diabetes mellitus and risk of Alzheimer disease and decline in cognitive function. Arch Neurol 2004; 61:661-666.
40. Schneider JA, Wilson RS, Cochran EJ et al. Relation of cerebral infarctions to dementia and cognitive function in older persons. Neurology 2003; 60:1082-1088.
41. Peters R, Beckett N, Forette F et al. Incident dementia and blood pressure lowering in the hypertension in the very elderly trial cognitive function assessment (HYVET-COG): a double-blind, placebo controlled trial. Lancet Neurol 2008; 7:683-689.
42. Cukierman-Yaffe T, Gerstein HC, Williamson JD et al. Relationship between baseline glycemic control and cognitive function in individuals with type 2 diabetes and other cardiovascular risk factors: the action to control cardiovascular risk in diabetes-memory in diabetes (ACCORD-MIND) trial; Action to Control Cardiovascular Risk in Diabetes-Memory in Diabetes (ACCORD-MIND) Investigators. Diabetes Care 2009; 32:221-226.
43. Maggi S, Limongi F, Noale M et al. LSA Study Group. Diabetes as a risk factor for cognitive decline in older patients. Dement Geriatr Cogn Disord 2009; 27:24-33.
44. Ikonomovic MD, Klunk WE, Abrahamson EE et al. Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease. Brain 2008; 131:1630-1645.
45. Whitmer RA, Karter AJ, Yaffe K et al. Hypoglycemic episodes and risk of dementia in older patients with type 2 diabetes mellitus. JAMA 15; 301:1565-1572.
46. Novak V, Abduljalil AM, Novak P et al. High-resolution ultrahigh-feld MRI of stroke. Magn Reson Imaging 2005; 23:539-548.
47. Kodl CT, Franc DT, Rao JP et al. Diffusion tensor imaging identifes defcits in white matter microstructure in subjects with type 1 diabetes that correlate with reduced neurocognitive function. Diabetes 2008; 57:3083-3089.
48. Zetterberg LO,Wahlund K, Blennow. Cerebrospinal fluid markers for prediction of Alzheimer's disease. Neurosci Lett 2003; 352:67-69.
49. Hansson H, Zetterberg P, Buchhave E et al. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol 2006; 5:228-234.
50. Ewers M, Buerger K, Teipel SJ et al. Multicenter assessment of CSF-phosphorylated tau for the prediction ofconversion of MCI. Neurology 2007; 69:2205-2212.
51. Gouw AA, van der Flier WM, Fazekas F et al. Progression of white matter hyperintensities and incidence of new lacunes over a 3-year period: the Leukoaraiosis and Disability study. Stroke 2008; 39:1414-1420.